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Abstract: Insulin, besides its pivotal role in energy metabolism, may also modulate neuronal processes
through acting on insulin receptors (InsRs) expressed by neurons of both the central and the peripheral
nervous system. Recently, the distribution and functional significance of InsRs localized on a subset
of multifunctional primary sensory neurons (PSNs) have been revealed. Systematic investigations
into the cellular electrophysiology, neurochemistry and morphological traits of InsR-expressing PSNs
indicated complex functional interactions among specific ion channels, proteins and neuropeptides
localized in these neurons. Quantitative immunohistochemical studies have revealed disparate
localization of the InsRs in somatic and visceral PSNs with a dominance of InsR-positive neurons
innervating visceral organs. These findings suggested that visceral spinal PSNs involved in nociceptive
and inflammatory processes are more prone to the modulatory effects of insulin than somatic PSNs.
Co-localization of the InsR and transient receptor potential vanilloid 1 (TRPV1) receptor with
vasoactive neuropeptides calcitonin gene-related peptide and substance P bears of crucial importance
in the pathogenesis of inflammatory pathologies affecting visceral organs, such as the pancreas and
the urinary bladder. Recent studies have also revealed significant novel aspects of the neurotrophic
propensities of insulin with respect to axonal growth, development and regeneration.
Keywords: insulin; insulin receptor; primary sensory neurons; capsaicin; TRPV1 receptor; pain;
diabetes; pancreatitis; inflammation; neurite outgrowth; neuropathy
1. Introduction
Insulin is a major hormone regulating the energy metabolism of the organism. Besides its
endocrine effects, insulin may modulate distinct neural functions through insulin receptors (InsRs)
expressed in neurons of the central and peripheral nervous system. Neuronal localizations of insulin
and InsRs have been first described in the central nervous system mostly in areas involved in the
regulation of energy balance and food intake [1]. Later studies disclosed widespread brain distribution
of InsRs [1–4], and also that of insulin, which is of peripheral (plasma) rather than neuronal origin [5].
Available data indicate that most insulin is made in the pancreas, and there is no convincing evidence
that insulin can be synthesized in the brain [5,6].
InsR, as a member of the receptor tyrosine kinase family, has a heterotetrameric structure with
two extracellular α and two transmembrane glycoprotein β subunits which contain the tyrosine kinase
domain. Insulin activates the InsR by binding to the α subunit of the receptor which induces the
phosphorylation of tyrosine residues of intracellular proteins such as the insulin receptor substrate (IRS)
proteins [7,8]. Phosphorylation of IRS proteins initiates the activation of phosphatidylinositol-3-kinase
(PI3K) which, in turn, activates protein kinase B (Akt) and protein kinase C (PKC) cascades, and growth
factor receptor bound protein 2/son of sevenless protein cascade which activates mitogen-activated
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protein kinase (MAPK) [7,9,10]. The Akt cascade is involved in the translocation of the glucose
transporter 4 into the plasma membrane, regulation of glycogen, protein and lipid synthesis and glucose
intake, while MAPK is related to the modulation of gene expression, proliferation and cell growth [11–14].
The tissue distributions of InsR and IRS proteins are different, suggesting their involvement in disparate
physiological mechanisms and differing pathophysiological processes [7,15–18].
In recent years, electrophysiological, immunohistochemical and functional studies demonstrated
the localization and functional significance of InsRs in primary sensory neurons (PSNs), in particular
nociceptive PSNs expressing the transient receptor potential vanilloid type 1 (TRPV1) receptor [19–25].
The present review attempts to summarize experimental data on the diverse roles of insulin and InsRs
in physiological and pathophysiological processes involving PSNs.
2. Subpopulation of Multifunctional Nociceptive PSNs Expressing TRPV1 Receptor
Nociceptive PSNs transmit impulses evoked by noxious mechanical, thermal and chemical
stimuli [26]. Morphologically, nociceptive PSNs are mostly dark, type B sensory ganglion cells emitting
thinly myelinated Aδ or unmyelinated C fibers [27–34]. It has been revealed that a group of nociceptive
PSNs, if stimulated, release vasoactive agents to produce local vascular reactions, vasodilatation and
plasma extravasation, collectively termed the neurogenic inflammatory response [35–38]. Nociceptive
PSNs have been suggested to possess not only afferent functions by transmitting nociceptive impulses
but also efferent/local regulatory functions through the release of vasoactive agents from their
stimulated peripheral nerve endings [35,36,38]. It has also been demonstrated that nociceptive PSNs
are sensitive to and can be selectively eliminated by capsaicin and comprise a morphologically,
neurochemically and functionally distinct subpopulation of somatic and visceral PSNs [33,34,39].
Chemo-/capsaicin-sensitive PSNs have been shown to express the TRPV1 ion channel, the capsaicin
receptor [40]. The TRPV1 receptor is generally regarded as a molecular integrator of nociceptive
stimuli and can be activated by noxious heat (~43 ◦C), acidic pH, and exogenous (capsaicin) and
endogenous vanilloids (e.g., anandamide) [41–44]. Furthermore, it has been revealed that various
agents released upon tissue damage and inflammation, such histamine, prostaglandin E2, bradykinin
and nerve growth factor (NGF) sensitize the TRPV1 receptor [44–47]. Capsaicin-sensitive PSNs
contain different neuropeptides, such as substance P (SP), calcitonin gene-related peptide (CGRP)
and somatostatin [48–50]. There is ample evidence for CGRP and SP mediating sensory neurogenic
vasodilatation and sensory neurogenic plasma extravasation, respectively [51–56]. Besides playing
a pivotal role in the initiation of vascular reactions, capsaicin-sensitive TRPV1 receptor expressing
peptidergic PSNs are also involved in local regulation of smooth muscle contraction/relaxation,
glandular secretion, immune reactions and other visceral functions [55–59]. Hence, neurons of this
particular subpopulation of capsaicin-sensitive PSNs are multifunctional: they are involved not only
in the transmission of nociceptive impulses, but also in local regulatory functions of the innervated
organs. Therefore, agents interfering with TRPV1 receptor function may modulate both the afferent
and local regulatory functions of PSNs.
Immunohistochemical studies have revealed that capsaicin-sensitive PSNs can be divided into
two major categories: peptidergic and non-peptidergic neurons. These subpopulations of PSNs have
different trophic factor sensitivities and neurochemical characteristics. TRPV1 receptor-expressing
peptidergic PSNs contain CGRP, SP, vasoactive intestinal polypeptide, galanin and neurokinin
A [48,50,60,61]. Non-peptidergic nociceptive PSNs express fluoride-resistant acid phosphatase,
equivalent to thiamine monophosphatase [62–67], an enzyme which has been recently identified
as prostatic acid phosphatase [68]. Furthermore, it has been revealed that non-peptidergic neurons
bind the isolectin B4 (IB4) from Bandeiraea simplicifolia [63,69]. Besides their different neurochemical
characteristics, peptidergic and non-peptidergic PNSs show disparate neurotrophin sensitivities as well.
Although, during the early postnatal period, peptidergic and non-peptidergic PSNs are responsive
to NGF and express the tropomyosin kinase A (TrkA), later non-peptidergic neurons lose their
NGF-sensitivity by the down-regulation of TrkA, and they become sensitive to glial cell line-derived
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neurotrophic factor and express the Ret [70–72]. Although, neurochemical characteristics and
neurotrophins sensitivities of peptidergic and non-peptidergic nociceptive neurons show differences,
up to 60% of neurons of these subcategories of PSNs express the archetypal nociceptive ion channel,
the TRPV1 receptor [22,23,40,73].
Characterization of the chemical phenotypes of PSNs have revealed the sensitivity to insulin
and the localization of InsRs in a sizeable subpopulation of neurons amounting to about 60 per
cent of spinal PSNs of unidentified target identity [19,22,23] Further, it has also been demonstrated
that insulin and insulin-like growth factor 1 (IGF-1) can also sensitize the TRPV1 receptor [19].
These findings suggested a possible interplay among insulin, InsR and TRPV1 receptor in PSNs under
pathophysiological conditions.
3. Neurochemical Characterization of Somatic and Visceral PSNs Expressing the InsR
Early light and electron microscopic studies demonstrated the presence of InsR immunoreactivity
in a population of small dorsal root ganglion (DRG) neurons and in Rexed’s laminae V and X of the
spinal cord [74]. At the ultrastructural level, InsR is localized on the axolemma, the Schwann cell loops
and the nodal microvilli of myelinated peripheral nerves [75]. Studies on cultured PSNs supported
these original findings by showing that about 50% of the neurons expressed the InsR and up to 30% of
the neurons showed colocalization of the TRPV1 receptor and the InsR [19]. Moreover, it has been
demonstrated that about half of the TRPV1 receptor-immunoreactive PSN neurons exhibited the InsR.
The colocalization of the InsR and neuropeptides has also been revealed: about 20% of InsR-expressing
mouse DRG neurons showed CGRP and/or IB4-immunoreactivity [22]. In addition, it has also been
demonstrated that there is no difference in the immunoreactivities of these markers between wild-type
and TRPV1 receptor knock out mice [22].
Later, the expression pattern of InsR and the co-localization the InsR with the TRPV1 receptor,
CGRP and IB4 have also been revealed in cultured rat DRG neurons. It has been demonstrated that
about half of the DRG neurons showed InsR-immunopositivity and about 60%, 50% and 30% of
InsR-expressing sensory neurons exhibited the TRPV1 receptor, CGRP and the IB4-binding glycoprotein,
respectively [23]. Furthermore, it has been revealed that about 60% and 50% of TRPV1 receptor- and
CGRP- or IB4-immunopositive cultured DRG neurons exhibited InsR-immunoreactivity [23].
The neurochemical phenotypes of InsR-expressing PSNs innervating different organs have also
been revealed. It has been demonstrated that about one-quarter of somatic (cutaneous and muscle)
and about half of visceral (urinary bladder and pancreatic) PSNs express the InsR [24]. In addition,
it has been demonstrated that the differences between the two subpopulations (somatic and visceral)
were significant [24]. However, about 60% of InsR-expressing PSNs innervating the dorsal hind
paw skin, the gastrocnemius muscle, the urinary bladder and the pancreas showed TRPV1 receptor
immunoreactivity [24]. These observations suggest that the majority of InsR-expressing PSNs are
nociceptive in nature.
The phenotypes of pancreatic spinal and vagal PSNs have been analyzed in more detail. It has been
demonstrated that about 50% of DRG and nodose ganglia (NG) neurons innervating the rat pancreas
express the InsR [25]. It has also been shown that up to 50% of InsR-expressing pancreatic spinal and
vagal PSNs exhibit TRPV1 receptor immunoreactivity [25]. Further, about 30% of InsR-expressing
pancreatic spinal and vagal sensory neurons contain SP. CGRP is contained in about 60% and 20%
of spinal and vagal PSNs, respectively [25]. Moreover, it has been revealed that up to 30% of TRPV1
receptor-expressing pancreatic spinal and vagal PSNs exhibit InsR immunoreactivity [25]. In addition,
up to one-quarter of CGRP or SP containing pancreatic spinal and vagal sensory neurons express the
InsR as well [25].
In summary, these quantitative immunohistochemical studies have revealed the disparate
localization of InsRs in somatic and visceral PSNs with dominance of neurons innervating visceral
organs. This suggests that visceral PSNs involved in nociceptive and inflammatory processes may be
more prone to the modulatory effects of insulin than somatic PSNs. Additionally, these studies have
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demonstrated that majority of InsR-expressing PSNs also display TRPV1 receptor immunoreactivity.
Importantly, these observations have revealed that the pancreas is innervated by a meshwork of
InsR-expressing spinal and vagal PSNs which contain sensory neuropeptides and express the TRPV1
receptor. These morphometric data implicate that an interaction among insulin, InsR, TRPV1 receptor
and sensory neuropeptides may play an important role in the development of pancreatic pathologies.
4. Effects of Insulin on TRPV1 Receptor-Expressing Nociceptive Neurons
Studies on cultured adult rat DRG neurons have revealed that insulin can sensitize the TRPV1
receptor toward the effect of the selective agonist capsaicin. It has been demonstrated that administration
of insulin enhances the accumulation of cobalt ions in capsaicin-stimulated neurons [19]. The cobalt
accumulation technique relies on the histochemical visualization of cobalt ions selectively taken up by
neurons expressing the non-selective cation channel TRPV1 upon stimulation with agonists, such as
capsaicin. Densitometric analysis of the precipitated cobalt ions is a reliable tool to estimate the
proportion and the reactivity of individual capsaicin-sensitive PSNs in culture [76,77]. An advantage
of this method is that cobalt ions enter the cells exclusively through the activated TRPV1 channels but
not through voltage sensitive Ca2+ or Na+ channels; hence, cobalt accumulation specifically indicates
changes in the conductance of plasma membrane TRPV1 channels upon agonist-induced activation [78].
The sensitizing effect of insulin could be reduced by inhibitors of tyrosine-kinase, phospholipase C
and PKC [19]. Furthermore, at the highest concentration applied (10 µM), insulin induced cobalt
accumulation per se indicating the activation of the TRPV1 receptor. The insulin-induced cobalt
accumulation was reduced by administration of both competitive and non-competitive antagonists of
the TRPV1 receptor, capsazepine and ruthenium red, respectively, further suggesting the involvement
of TRPV1 receptor in the action of insulin. Whole-cell voltage clamp experiments disclosed that
acute administration of insulin induced inward currents in subsets of cultured PSNs of both the
rat (18%) and the mouse (9%) in the concentration range of 300 nM-10 µM [22,79]. All neurons
responding to insulin were also sensitive to capsaicin, and ruthenium red at concentrations sufficient
to block capsaicin-induced currents also abolished the insulin-induced currents. Importantly, in
cultures prepared from DRGs taken from TRPV1 receptor knock out mice, both the number of neurons
showing activation of inward current following insulin application and the maximal current intensity
evoked by insulin were significantly lower compared to data obtained from wild type PSNs [79].
These results strongly suggest, that besides its long-term neurotrophic effects, insulin may modulate
the chemo- and thermosensitivity of nociceptive PSNs co-expressing the TRPV1 receptor and the
InsR. Insulin-mediated sensitization of the TRPV1 receptor currents induced by chemical or thermal
stimulations were also demonstrated in heterologous expression systems and isolated embryonic DRG
neurons [20]. The sensitizing effect of insulin is mediated in part by rapid translocation and insertion
of TRPV1 channels into the plasma membrane, an effective mechanism to increase the sensitivity of
sensory neurons toward noxious stimulation.
Furthermore, increased expression of TRPV1 receptor protein has been demonstrated following
long-term administration of IGF-1 and insulin in TRPV1 receptor-expressing neuroblastoma cells.
In addition, it has been disclosed that expression of TRPV1 receptor protein is decreased by inhibiting
the MAPK and PI3K cascades. These findings suggested a crucial role of MAPK and PI3K signaling
pathways in the regulation of the TRPV1 receptor by IGF-1 and insulin [21]. In accord with these
observations, the involvement of PI3K and PKC cascades has also been demonstrated in the regulation
of TRPV1 receptor mediated membrane currents, which are enhanced by IGF-1 and insulin [20].
Similarly, acute administration of NGF has been shown to induce translocation of intracellular
TRPV1 receptors into the plasma membrane, underlying its sensitizing effect on the TRPV1 channel [80].
It is worth to mention, that IGF-1, widely expressed and secreted in different tissues, can also
sensitize [20] and activate [79] cultured nociceptive neurons. It has also been shown that long-term
application of insulin modifies the expression of the TRPV1 receptor protein in neuroblastoma cells
by regulating the PI3K and MAPK signaling [21]. Additionally, in a recent publication it has been
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demonstrated, that selective chemodenervation evoked by neonatal capsaicin treatment resulted in
changes in myocardial miRNA expression targeting among others the expression network of IGF-1 [81].
Studies utilizing calcium imaging demonstrated the activation of a subset of mouse NG neurons by
insulin in a dose-dependent manner [82]. All neurons which were sensitive to insulin were also sensitive
to capsaicin and expressed the TRPV1 receptor. By using selective antagonists, the involvement of
L-type (verapamil) and N-type (ω-conotoxin) voltage-sensitive Ca-channels in the activation of NG
neurons by insulin has also been revealed. These findings suggested that apart from TRPV1, other (Ca)
channels are also involved in the direct activation of sensory neurons by insulin. To demonstrate
the direct involvement of InsR signaling in the insulin-mediated effect, a genetically modified mice
strain was used. Genetic deletion of the insulin receptor substrate type 2 protein (IRS2) completely
inhibited the insulin-induced depolarization and calcium influx in cultured NG neurons. Similarly,
blocking of PI3K, one of the main intracellular messengers of the insulin signal resulted in a marked
reduction in the incidence of calcium responses to insulin. These data indicated that the signal cascade
InsR-IRS2-PI3K plays an essential role in the activation of NG neurons by insulin, although other
pathways may also be involved [82]. Importantly, it has been shown that more than 50% of neurons
responsive to insulin expressed the neuropeptide cocaine and amphetamine regulated transcript
(CART). Since CART exerts powerful anorexigenic actions in both the hypothalamus and the nucleus
of the solitary tract, an involvement of insulin-sensitive pancreatic vagal afferents in the regulation of
food intake, satiety and metabolism has been proposed [82].
5. Contribution of TRPV1 Receptor- and InsR-Expressing PSNs to Pancreatic and Urinary
Bladder Pathologies
It has been demonstrated that a TRPV1 receptor antagonist, capsazepine decreases the expression
level of neurokinin-1 receptor, the receptor of SP, the pancreatic enzymes associated with pancreatitis,
and the severity of histological changes in caerulein-induced experimental pancreatitis in mice.
These findings suggested the importance of the TRPV1 receptor expressing SP-immunopositive fibers
in pancreatic pathologies [83]. Furthermore, it has been revealed that neonatal capsaicin treatment
causes a significant decrease of inflammatory markers and histological changes of the pancreas in
experimental acute pancreatitis [84]. Other studies have demonstrated that the expression of the TRPV1
receptor is increased in DRG neurons during the development of chronic pancreatitis [85]. Moreover,
it has been revealed that administration of TRPV1 receptor antagonists reduce the severity of acute
pancreatitis [86]. These findings have provided evidence for a crucial role of the TRPV1 receptor in the
mediation of pathologies of the exocrine pancreas.
The TRPV1 receptor is also expressed in the endocrine pancreas, and it has also been demonstrated
that activation of the TRPV1 receptor can modulate the glucose-induced insulin secretion of pancreatic
islet β cells [87,88]. The direct effect of sensory neuropeptides on pancreatic islet β cells has also been
revealed [89–92]. Previous studies have demonstrated that pancreatic islets are innervated by TRPV1
receptor expressing sensory nerves which can be eliminated by neonatal capsaicin treatment [91].
Interestingly, in an experimental model of type 1 diabetes mellitus (non-obese diabetic (NOD) mice)
neonatal capsaicin treatment delayed the onset of diabetes and reduced its incidence compared to
control NOD mice. It has also been revealed that neonatal capsaicin treatment reduced the accumulation
of inflammatory cells including T-cells throughout the islets. Importantly, it has also been revealed that
TRPV1 receptor protein expression is decreased in control NOD mice [91]. Furthermore, it has been
demonstrated that pancreatic PSNs which contain sensory neuropeptides have a protective role against
the development of diabetes mellitus [91,93]. It has also been shown that systemic administration of
capsaicin prevents the development of decreased glucose tolerance in an animal model (Zucker diabetic
rat) of type 2 diabetes mellitus [94]. Importantly, a novel study has demonstrated that administration of
a TRPV1 receptor antagonist improved the glucose-stimulated insulin secretion and glucose tolerance
in Zucker diabetic rats [95]. These studies suggested the importance of sensory neurons expressing
the TRPV1 receptor in the mediation of pancreatic pathologies. Recently, loss of InsRs expressed by
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pancreatic sensory nerves has been shown to result in elevated insulin levels and reduced glucose
tolerance in sensory neuron insulin receptor knock out (SNIRKO) mice [96].
Recent work has indicated that the TRPV1 receptor may play an important modulatory role in
glucose-induced insulin secretion as well. It has been demonstrated that TRPV1 receptor knock out
mice show significantly higher blood glucose levels, and a higher decrease in glucose induced insulin
secretion compared with wild type mice [97]. Additionally, it has been revealed that capsaicin can
increase pancreatic insulin secretion of wild-type, but not of TRPV1 receptor knock out animals [97].
Furthermore, it has been shown that high glucose stimulation causes significantly higher pancreatic
CGRP and SP release in wild-type compared to knock out mice. Interestingly, administration of TRPV1
receptor, CGRP or SP antagonists reduced insulin secretion in wild-type, but not in knock out mice [97].
This study supported previous findings by showing an important role of TRPV1 receptor and sensory
neuropeptides in the regulation of glucose-induced insulin secretion of the pancreas. Another study
demonstrated that intragastric administration of allyl isothiocyanate, which is a potent agonist of the
transient receptor potential ankyrin type 1 (TRPA1) receptor and activates the TRPV1 receptor as well,
elevates plasma insulin levels in mice by directly stimulating insulin secretion from the pancreas [98].
Moreover, it has been revealed that in TRPV1 receptor knock out mice, the allyl isothiocyanate-induced
insulin secretion was lower compared to TRPV1 receptor wild-type animals [98].
Taken together, these studies have demonstrated that insulin may potentiate the release of
inflammatory neuropeptides by sensory nerves innervating the islet apparatus and the exocrine
pancreas through direct and/or indirect modulation of TRPV1 receptors [82,86,91,94,99–102]. Further,
neuropeptides contained in sensory nerves, such as SP and CGRP may modulate inflammatory
processes of both the endocrine and exocrine pancreas. Quantitative immunohistochemical findings
supported these findings by showing that the majority of pancreatic vagal and spinal DRG neurons
express the TRPV1 receptor, the InsR and sensory neuropeptides [25].
The role of capsaicin-sensitive sensory nerves in the function and pathologies of the urinary bladder
is well established. Functional morphological studies have shown that a high proportion of sensory
nerves which innervate the urinary bladder are mostly unmyelinated and capsaicin-sensitive [59,103].
Activation of these TRPV1 receptor expressing nerves has been shown to produce contraction of
the bladder smooth muscle and reflex micturition. Depletion of sensory neuropeptides by systemic
pretreatment with capsaicin greatly inhibited or even abolished reflex micturition in rats [104].
Capsaicin-sensitive nerves have been implicated in human bladder pathologies such as pain associated
with overactive bladder [105,106]. Intravesical capsaicin has been shown to ameliorate symptoms of
detrusor hyperreflexia and is in clinical use to treat this condition [107]. A decrease in TRPV1 receptor
agonist-induced urinary bladder contraction has been shown in streptozotocin-induced experimental
diabetes [108]. This may be explained by a loss of sensory nerves, impaired axonal transport or
expression of the TRPV1 receptor [108]. Importantly, changes in TRPV1 receptor gene expression may
also contribute to a decrease of TRPV1 receptor agonist-induced smooth muscle contraction since,
in neuroblastoma cells, TRPV1 receptor gene transcription has been shown to be insulin-dependent [21].
Insulin has also been shown to restore the TRPV1 receptor-mediated vasodilatatory response of
dura mater arterioles in streptozotocin diabetic rats [109]. Activation of capsaicin-sensitive afferent
nerves, through the release of pro-inflammatory peptides SP and CGRP, has also been shown to
contribute to urinary bladder inflammation induced by cyclophosphamide [110]. These findings
suggest interactions among TRPV1 receptors, insulin and the InsRs which may significantly modulate
functions of different organs, including urinary bladder smooth muscle contractility, inflammation and
nociception. It is also to be noted, however, that several studies have demonstrated that insulin inhibits
general inflammatory processes as well. It has been revealed that insulin suppresses the expression of
inflammatory chemokines such as nuclear factor-kappaB and monocyte chemoattractant protein-1
in vitro [111]. Additionally, it has been shown that in vitro treatment with insulin decreases tumor
necrosis factor and interleukin 6 expression by regulating the PI3K-Akt cascade [112,113].
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6. Role of TRPV1 Receptor, InsR and Insulin in the Development of Complications Associated
with Diabetes Mellitus
Over the past few years, many reports have indicated that nociceptive sensory neurons are
involved in the development of diabetic peripheral neuropathy and diabetic visceral hypo- or
hypersensitivity [91,99,114–120]. Furthermore, there is growing evidence that supports an important
role of TRPV1 receptor-mediated neuroinflammation through the release of sensory neuropeptides in
the development of diabetic peripheral neuropathy [121].
Recent work using immunohistochemistry and western blot analysis has revealed that expression
of TRPV1 receptor and CGRP decreased in spinal cord dorsal horn of in rats with streptozotocin (STZ)
diabetes. It has also been demonstrated that expression of these markers were also reduced in peripheral
nerves [122]. In addition, it has been shown that ropivacaine, which is a commonly used anesthetic in
the treatment of peripheral neuropathy, has a protective effect against the development of diabetic
peripheral neuropathy by regulating TRPV1 receptor mediated CGRP release [122]. In agreement with
this study, another report has demonstrated that TRPV1 receptor antagonists such as capsazepine
prevent hydrogen sulfide-induced hyperalgesia in diabetic rats [123]. This work suggested that TRPV1
receptor blockers could be a therapeutic target for the treatment of diabetic peripheral neuropathy [123].
Additionally, in the past decade, several lines of evidence have suggested that insulin has a
direct role on PSNs and insulin signaling may be involved in the development of diabetic peripheral
neuropathy [124–127]. Regarding the potent neurotrophic effect of insulin, recent studies have
indicated that beside glucose toxicity, insulinopenia and hyperinsulinemia may be important pathogenic
components of diabetic peripheral neuropathy and visceral hypo- and hypersensitivity [25,126–129].
It has also been revealed that insulin infusion causes a decrease in CGRP-mediated sensory
neurogenic vasodilatation in rats [116]. Furthermore, it has been demonstrated that chronic
hyperinsulinemia induced by fructose (fructose-drinking rats, FDR) also inhibits the vasodilatation
mediated by peptidergic sensory fibers [117]. Interestingly, it has been revealed that DRGs of FDRs
showed a decreased CGRP content and reduced density of CGRP-immunoreactive fibers in mesenteric
arteries [119]. Moreover, in the last decade, several reports has demonstrated that mitochondrial
dysfunction of DRG neurons is involved in the development of diabetes mellitus [130–132]. It has also
been proposed that loss of insulin signaling is involved in the development of mitochondrial changes of
DRGs [126,133,134]. Interestingly, a recent study has revealed that insulin promotes mitochondrial gene
expression of cultured DRG neurons derived from control and STZ- diabetic rats [135]. Additionally,
it has also been demonstrated that insulin treatment enhanced thermal sensitivity and increased
dermal nerve density in diabetic animals [135]. It has also been shown that chronic administration of
fructose, which induces insulin resistance, and neuropathic pain, reduced InsR protein expression in
DRGs and sciatic nerve [123]. However, it has also been revealed that SNIRKO mice do not show any
physiological, morphological or behavioral signs of diabetic peripheral neuropathy [96].
In summary, these studies suggested a significant role of the TRPV1 receptor in the development
of diabetic peripheral neuropathy and visceral hypo- or hypersensitivity. Although some of
these experiments suggested that impairments in neuronal insulin signaling may contribute to
the development of diabetic neuropathy, the role of interactions among insulin, InsRs and the TRPV1
receptors in these processes have not yet been evaluated in detail.
7. Role of Insulin and InsRs in Neurite Outgrowth and Regeneration of PSNs
Early studies have revealed that insulin has a potent neurite outgrowth-promoting effect on
cultured adult rat sensory and sympathetic neurons [136]. Further, it has also been demonstrated that
insulin promotes the neurite outgrowth of human neuroblastoma cells as well [137]. Following these
observations, several studies have attempted to reveal the exact molecular mechanisms of insulin’s
neurite outgrowth-promoting effects on sensory neurons.
Recent observations confirmed and extended the findings of previous reports on the neurite
growth promoting effect of insulin. It has been revealed that insulin modulated neurite outgrowth
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in a concentration dependent manner. In cultured DRG neurons insulin administered at low (nM)
concentrations elicited a growth promoting effect, whereas at micromolar concentrations an inhibition
of axon growth was observed [138]. Importantly, in cultured DRG neurons, a significantly enhanced
neurite growth promoting effect of insulin was observed in neurons which express the InsR, as compared
to neurons which do not [23]. It has also been shown that insulin promotes axon growth by stabilization
of tubulin mRNA levels [139].
The exact molecular background of insulin’s neurite outgrowth promoting effect has not yet been
evaluated in detail. However, in the light of previous observations, it could be hypothesized that the
interaction between insulin and the InsR by activating the PI3-Akt pathway [140,141], that is directly
related to axonal growth, has a significant effect on neurite outgrowth of DRG neurons. Recent work
has also shown that administration of high (µM concentrations of insulin, through the desensitization
of the InsRs, render DRG neurons less sensitive to neurite outgrowth-promoting actions of insulin
by inhibiting the PI3K-Akt pathway [141]. Furthermore, it has been revealed that increase of GSK-3b
levels may contribute to the decreased sensitivity of DRG neurons to insulin [141,142].
Although, these studies suggested a crucial role of the InsR in neurite growth, it has also
been demonstrated that the InsR forms a molecular complex with the TrkA in PC12 cells which
show similarities with nociceptive sensory neurons [143]. Further, it has been demonstrated that
TrkA is involved in insulin signaling by regulating the MAPK or Akt cascades [143]. TrkA, as a
transmembrane receptor tyrosine kinase for NGF, is involved in neuronal survival and differentiation
of PSNs (Silos-Santiago, 1995, Molliver). Thus, it may be assumed that the InsR and TrkA are involved
in the mediation of the neurite outgrowth-promoting effect of insulin on nociceptive PSNs. This is
supported by recent findings showing a preferential neurite outgrowth promoting effect of insulin
on InsR-immunoreactive peptidergic subpopulations of cultured adult rat PSNs [23]. Available
experimental evidence indicates that ganglioside GM1 is significantly implicated in the mediation of
the neurotrophic effect of NGF in primary sensory neurons [144]. TRPV1 receptors are associated with
and regulated by GM1, an important constituent of membrane lipid rafts [145–147]. Since InsRs are
recruited upon ligand binding to membrane lipid microdomains [148], an interaction of the InsR with
the TRPV1 receptor at the lipid raft domains of the plasma membrane cannot be excluded.
Importantly, in vivo studies have revealed that intrathecal [149] or systemic [150] administration
of insulin stimulated the regeneration of injured peripheral nerves. IGF-I has also been shown to
promote regeneration of sciatic nerve afferent fibers after local application to relating dorsal root
ganglia or directly onto the injured nerve. Importantly, application of antibodies against IGF-I resulted
in a significant reduction of axonal regeneration, suggesting a role for endogenous IGF-I in nerve
regeneration [151]. In addition, local administration of IGF-II has been shown to enhance regeneration
of motor axons following a crush injury. In contrast, spontaneous regeneration was inhibited by
local application of an anti-IGF antiserum to the injured nerve [152]. Recent findings suggest that the
neurotrophic effects of insulin and IGF-1, similarly to NGF, may be mediated through activation of
TrkA [143]. TrkA is also involved in the development of the neurochemical phenotypes of nociceptive
PSNs and, importantly, the expression of the TRPV1 receptor is regulated by NGF [77,153]. Since TrkA
seems to be a common target of both insulin and NGF, a possible role of insulin and InsRs in the
phenotypic regulation of nociceptive neurons cannot be excluded.
In vivo experiments have also indicated an increased insulin sensitivity of peptidergic PSNs.
Thus, it has been revealed that administration of intrathecal insulin increased the expression of CGRP
in regenerating nerve fibers and DRG neurons after nerve injury [149]. Additionally, it has also
been demonstrated that local insulin treatment promoted the regeneration of myelinated fibers and
small-fiber sprouting in streptozotocin diabetic rats [154]. Recent quantitative immunohistochemical
data demonstrated that CGRP-immunoreactive PSNs displayed increased neurite outgrowth, axonal
branching and neurite length as compared to CGRP-negative neurons. It has also been shown in these
experiments that insulin did not increase neurite elongation of non-peptidergic PSNs [23]. Interestingly,
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streptozotocin, an agent used to induce experimental diabetes mellitus, has a direct effect on PSNs by
increasing the expression of the TRPV1 receptor and the TRPV1 receptor-mediated CGRP-release [155].
Several reports have demonstrated that the density of CGRP-expressing perivascular sensory
fibers and the CGRP content of DRGs decreased in mice with experimental insulin resistance [116–119].
In particular, these reports have also revealed that these fibers respond poorly to the trophic actions of
exogenous NGF as compared to controls [118,119]. Similarly, capsaicin-induced release of CGRP and
the density of CGRP and TRPV1 receptor expressing sensory fibers were markedly decreased in the
dura mater of diabetic rats as compared to controls [109]. Hyperinsulinemia has been shown to induce
insulin resistance of DRG neurons through hyperphosphorylation of the InsR by an Akt-mediated
pathway, and the increase in the expression of GSK-3-β [156]. It has also been demonstrated that PSNs
develop resistance to the trophic actions of insulin by the downregulation of InsR mRNA [141].
8. Conclusion and Perspectives
Besides its fundamental significance in energy metabolism, a significant role of insulin in
modulation of neural functions has emerged. InsRs are expressed mostly on nociceptive TRPV1
receptor expressing PSNs innervating somatic and visceral organs with predominance in the latter.
InsRs are involved in mechanisms of organ pathologies, in particular inflammatory processes of
both the exocrine and endocrine pancreas. Experimental evidence indicates a pivotal role of TRPV1
receptor expressing PSNs in the pathomechanism of acute pancreatitis. Pancreatic TRPV1 receptor-
and InsR-expressing peptidergic afferent nerves are also implicated in the mechanism of insulitis and
islet dysfunction contributing to the development of type 1 diabetes mellitus.
Figure 1 summarizes the mostly interrelated functional roles of insulin and the InsR and the
TRPV1 receptor at system, organ and cellular levels. Although the significance of modulation of
TRPV1 receptor function in the therapeutic management of pain, inflammatory states and neurogenic
dysfunction, such as overactive bladder is now well established [157], further studies are warranted to
exploit the possible therapeutic value of the observations summarized in this review. InsRs expressed
on PSNs play a significant role in the mechanisms of neurite outgrowth of cultured PSNs and axonal
regeneration in vivo. The exploration of the possible significance of these findings in relation to
the mechanism and therapy of neuropathic pathologies associated with diabetes mellitus awaits
future studies.





Figure 1. Insulin acts as a neuroactive substance by modulating the insulin (InsR) and transient receptor
potential vanilloid type 1 (TRPV1) receptors at system, organ and cellular levels. The involvement of
the InsR and the TRPV1 receptor in some physiological and pathophysiological processes is indicated.
Percent values show proportions of dorsal root ganglion neurons expressing the InsR and the TRPV1
receptor innervating the organ.
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